캔 파이트 바이오파마 ADR (CANF) 주가

캔 파이트 바이오파마 ADR(CANF)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.26 (+0.89%), 시가총액 $0.01B, 52주 최저~최고 $0.17 ~ $6.02.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It off

핵심 지표

• 현재가: $2.26 (+0.89%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.17 ~ $6.02
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NYSE MKT

캔 파이트 바이오파마 ADR의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

캔 파이트 바이오파마 ADR 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 1.25
• 순이익률: 0.00%
• 영업이익률: -24.89%

자주 묻는 질문